Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis.

Hyperimmune caprine serum (HICs) is a novel biologic therapy with potential benefits for the skin at established diffuse systemic sclerosis skin. Here we report a multiplex protein analysis of blood samples from the placebo-controlled clinical trials in phase II and explore the mechanism of action and response marker.

Patients treated with HICs (n = 10) or placebo (n = 10) over 26 weeks, with a follow up open-label treatment for 52 weeks in 14 patients. Serum or plasma samples at baseline, 26 and 52 weeks were analyzed using a multiplex immunoassay Monkey Recombinant Proteins or individuals for 41 proteins. The fringe pattern is analyzed by grouping using NetWalker 1.0, coefficient of Pearson and significance analysis of microarrays (SAM) correction.

cluster analysis, and multiplex testing SAM individual pairwise comparisons of protein analytes are identified that are regulated or downregulated during treatment with HICs. There upregulation of hypothalamic-pituitary-adrenal after treatment HICs evidenced by an increase in α-MSH and ACTH in cases treated with HICs. Interestingly, a significant increase in PIIINP was associated with improved treatment and MRSS HICs suggest that this may be a marker of extracellular matrix turnover.

 Other factors relevant HICs reduced in patients treated compared with controls, although not reaching statistical significance, including COMP, CCL2, IL6, TIMP2, fractalkine and TGFβ1 level.

Our results demonstrate the mechanism of action for HICs, including upregulation of α-MSH, which has proven anti-fibrosis in preclinical models, and may be markers for inclusion in future trials targeting diffuse systemic sclerosis skin on skin.

Small ruminants utilizing lentiviral Vif protein cyclophilin A in general, and structural evolutionary conserved protein, to reduce ovin and caprine APOBEC3 protein.

Mammals have co-evolved with retroviruses, including lentiviruses, in the long term. Evidence in support of this argument is that the viral infectivity factor (Vif) encoded by a lentivirus antagonizes the action of anti-virus mobile apolipoprotein B mRNA editing enzyme catalytic polypeptide such as 3 (APOBEC3) of the host. 

To set the E3 ubiquitin ligase complex for degradation APOBEC3, Vifs utilizing mammalian proteins such as core binding factor beta (CBFB, because primate lentivirus) or cyclophilin A (CYPA, because the virus Maedi-Visna [MVV]). However, the co-evolutionary relationship between mammals lentiviral Vif protein associated with Vif-mediated degradation of APOBEC3 poorly understood.

 Moreover, it is unclear whether the small ruminant Other Recombinant Proteins lentivirus Vif protein (SRLVs), including MVV and caprine arthritis encephalitis virus (CAEV), generally utilizing CYPA to reduce APOBEC3 of their host. In this study, molecular phylogenetics and homologous protein modeling revealed that Vif co-evolutionary and structural factors preserved. It was also found that not only MVV but also CAEV APOBEC3 Vifs lowering of both sheep and goats and that CAEV Vifs interact with CYPA